RET G810C

CI-VAR-00001832Explore in graph →CIViC 3226

Curated evidence

Evidence by cancer (2 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–2 of 2 evidence items across 2 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Lung Non-Small Cell Carcinoma1
KIF5B::RET Fusion AND ( RET G810C OR RET G810S OR RET G810R )	Selpercatinib	Predictive	C	Supports Resistance	4	accepted	EID8195 A 61-year old patient with KIF5B-RET fusion positive NSCLC received clinical benefit from selpercatinib treatment initially. ctDNA surveillance showed the emergence of RET G810S 3 months after the sta… (full text at CIViC) PMID 31988000 · Solomon et al., 2020 · Open in CIViC	civic
Malignant Neoplasm1
RET G810C	Pralsetinib + SelpercatinibSubstitutes	Predictive	C	Supports Resistance	4	submitted	EID8918 Cell-free DNA was analysed in a patient with RET-mutant (M918T and V804M) medullary thyroid cancer and another patient with CCDC6-RET fusion positive non-small cell lung cancer who had developed acqui…

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.